In vitro and in vivo activity of liposome‐encapsulated curcumin for naturally occurring canine cancers

Abstract

Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.

From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

“…The majority of those studies were performed in vitro (49 studies); 15 used xenografted mice to study CMC (in total, 15 papers of mouse models of CMTs). Only six of those investigations done with CMC cells in vitro or in mouse models, have reached the clinical setting ( 138 , 143 , 239 , 332 , 333 , 341 , 345 , 399 ).…”

“…Cell proliferation was effectively inhibited with the treatment; likewise, the viability, migration, and tube formation of endothelial cells were suppressed. In the same study, a pilot clinical trial was conducted with cancer-bearing dogs (CMC, pulmonary carcinoma, thyroid carcinoma, chest wall sarcoma, osteosarcoma, and malignant melanoma), achieving stable disease in ~60% of dogs ( 399 ). Finally, a combination of curcumin and paclitaxel was loaded into silica nanoparticles and delivered into CMC cell lines, manifesting a clear and persistent cytotoxic effect ( 400 , 401 ).…”

Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy

“…For osteosarcoma, several researchers have successfully proven that curcumin can induce the MG63, U2OS, and HOS cell line apoptosis based on different signal pathways (32,33,(47)(48)(49)(50). Besides, curcumin has also been identified to suppress the proliferation, invasion, and metastasis of osteosarcoma (23,24,51,52). Thence, curcumin is a promising agent with multifaced roles it plays in the treatment of osteosarcoma.…”

Efficacy of curcumin on prevention of drug‐induced nephrotoxicity: A review of animal studies

“…Intraperitoneal (IP) delivery has also proven effective against cancer, bleomycin‐induced injury, and allergic airway inflammation . In some cases, including cancer, curcumin has been administered intravenously …”

“…59 In some cases, including cancer, curcumin has been administered intravenously. [60][61][62][63] Two main concerns have been raised regarding the dosage and use of curcumin in managing and controlling DIN. First, curcumin is a chemically unstable substance that is practically insoluble in water at room temperature.…”